パリカルシトール (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "パリカルシトール" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

447^th place

1,043^rd place

low place

low place

1clinicaltrials.gov

5,225^th place

low place

clinicaltrials.gov

“clinicaltrials.gov”. 2011年4月23日閲覧。

fda.gov

accessdata.fda.gov

“label approved on 04/06/2011”. Food and Drug Administration. 2011年4月23日閲覧。

nih.gov

ncbi.nlm.nih.gov

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. (2010). “Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.”. Lancet 376 (9752): 1543-51. PMID 21055801.
Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. (1998). “19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.”. J Am Soc Nephrol. 9 (8): 1427-32. PMID 9697664.

pubmed.ncbi.nlm.nih.gov

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. (2010). “Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.”. Lancet 376 (9752): 1543-51. PMID 21055801.
Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. (1998). “19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.”. J Am Soc Nephrol. 9 (8): 1427-32. PMID 9697664.

whocc.no

“WHOCC ATC/DDD Index”. World Health Organization. 2011年4月23日閲覧。